Virility Medical Initiates Legal Action Against Morari Medical for Patent Violation
Virility Medical Ltd., an innovative leader in sexual health solutions, has recently taken a significant legal step by filing a patent infringement lawsuit against Morari Medical. The action, initiated on March 18, 2025, in the United States District Court for the District of Delaware, has drawn attention within the healthcare industry, particularly due to its implications surrounding intellectual property rights and product differentiation.
The lawsuit claims that Morari Medical's recently launched MOR product infringes upon three U.S. patents held by Virility Medical. These patents pertain to Virility Medical's in2 device, which has received clearance from the FDA. Formerly referred to as vPatch, the in2 device is designed for drug-free treatment of premature ejaculation, a prevalent issue affecting male sexual health. The specific patents listed in the lawsuit are U.S. Patent Nos. 10,773,072; 11,471,666; and 12,194,289.
In the filed complaint, Virility Medical underscores that Morari's MOR product not only mimics its technological advancements but also claims equivalence to the in2 device in its FDA submission documentation. This assertion by Morari’s CEO, Jeff Bennett, stating that the company has 'leveraged' Virility's pre-existing research to facilitate the expedited development of the MOR product, has raised eyebrows. It suggests that the MOR product may have incorporated elements of Virility’s proprietary technology without authorization, thereby infringing on their intellectual property.
Virility Medical is pursuing treble damages, which if awarded, would significantly increase the financial consequences for Morari Medical, reflecting the seriousness of the infringement claim. Additionally, the lawsuit seeks a permanent injunction to halt the sale of the MOR product, emphasizing the urgency and importance of protecting Virility's patented innovations.
Founded with a commitment to enhancing sexual wellbeing, Virility Medical has established a solid foothold in the sexual health market through its patented technology and rigorous clinical testing processes. Their in2 device has been recognized for its effectiveness and has gained approval from multiple regulatory bodies, including the FDA and the Israeli Ministry of Health, indicating strong support for its use among healthcare professionals.
As the litigation unfolds, it will not only affect the involved parties but may also set significant precedents within the medical device industry regarding patent rights and competition. Patent infringement cases like this one underscore the importance of innovative protection and the challenges companies face in safeguarding their intellectual property against rapidly evolving market competitors.
Looking ahead, industry experts will watch closely how this case develops, as the outcome may influence future guidelines on patent law and technology usage within the health sector. For now, Virility Medical remains focused on protecting its innovations while continuing to advance solutions for male sexual health concerns. The implications of this lawsuit extend beyond the laboratory and courtrooms; they could redefine standards for ethical competition in a space where innovation and intellectual property are vital to success.
The lawsuit claims that Morari Medical's recently launched MOR product infringes upon three U.S. patents held by Virility Medical. These patents pertain to Virility Medical's in2 device, which has received clearance from the FDA. Formerly referred to as vPatch, the in2 device is designed for drug-free treatment of premature ejaculation, a prevalent issue affecting male sexual health. The specific patents listed in the lawsuit are U.S. Patent Nos. 10,773,072; 11,471,666; and 12,194,289.
In the filed complaint, Virility Medical underscores that Morari's MOR product not only mimics its technological advancements but also claims equivalence to the in2 device in its FDA submission documentation. This assertion by Morari’s CEO, Jeff Bennett, stating that the company has 'leveraged' Virility's pre-existing research to facilitate the expedited development of the MOR product, has raised eyebrows. It suggests that the MOR product may have incorporated elements of Virility’s proprietary technology without authorization, thereby infringing on their intellectual property.
Virility Medical is pursuing treble damages, which if awarded, would significantly increase the financial consequences for Morari Medical, reflecting the seriousness of the infringement claim. Additionally, the lawsuit seeks a permanent injunction to halt the sale of the MOR product, emphasizing the urgency and importance of protecting Virility's patented innovations.
Founded with a commitment to enhancing sexual wellbeing, Virility Medical has established a solid foothold in the sexual health market through its patented technology and rigorous clinical testing processes. Their in2 device has been recognized for its effectiveness and has gained approval from multiple regulatory bodies, including the FDA and the Israeli Ministry of Health, indicating strong support for its use among healthcare professionals.
As the litigation unfolds, it will not only affect the involved parties but may also set significant precedents within the medical device industry regarding patent rights and competition. Patent infringement cases like this one underscore the importance of innovative protection and the challenges companies face in safeguarding their intellectual property against rapidly evolving market competitors.
Looking ahead, industry experts will watch closely how this case develops, as the outcome may influence future guidelines on patent law and technology usage within the health sector. For now, Virility Medical remains focused on protecting its innovations while continuing to advance solutions for male sexual health concerns. The implications of this lawsuit extend beyond the laboratory and courtrooms; they could redefine standards for ethical competition in a space where innovation and intellectual property are vital to success.
Topics Policy & Public Interest）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.